Sterne Agee Starts Endo Pharmaceuticals (ENDP) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Endo Int'l (ENDP) Unit Receives FDA Warning Letter Tied to Form 483 Notice
April 16, 2014 8:25 AM EDTAs previously reported in Endo Health Solutions Inc.s Form 10-K filed with the SEC on March 3, 2014, in February 2014, the United States Food and Drug Administration (the FDA) conducted an inspection of the Minnetonka, Minnesota facility of American Medical Systems, Inc. (AMS), a subsidiary of Endo International plc (Nasdaq: ENDP). Following such inspection, the FDA issued three observations on a Form 483 Notice of Inspectional Observations dated February 24, 2014 (the Form 483 Notice). These observations, previously self-identified by AMS, were being addressed through a corrective action plan which AMS originally expected to complete beyond 2015.
AMS provided the FDA an... More
